If you are searching for Cleerly heart scan locations, you already understand that calcium scores provide incomplete information. Cleerly quantifies what standard scoring misses.
Last updated: January 25, 2026
Standard cardiac CT imaging produces a coronary artery calcium (CAC) score. This metric quantifies calcified plaque, the stable, hardened deposits that develop over time. A higher score correlates with increased cardiovascular risk. A score of zero is often interpreted as reassuring.
The limitation is that calcified plaque is stable plaque. The dangerous variety, soft plaque, is not calcified. It is lipid-rich, unstable, and prone to rupture. Most heart attacks result from rupture of soft plaque, not erosion of calcified deposits. A patient with a zero calcium score may harbor significant soft plaque that the standard scoring method cannot detect.
Cleerly uses artificial intelligence to analyze coronary CT angiography (CCTA) images in detail. The platform quantifies total plaque burden, differentiates between plaque types (calcified, fibrous, lipid-rich), and measures stenosis percentage with precision that visual interpretation cannot match.
Cleerly is an analysis platform, not an imaging provider. The process requires obtaining a CCTA scan from a compatible imaging center, then having those images analyzed through Cleerly's AI platform.
Cleerly maintains a directory of compatible imaging centers at cleerlyhealth.com/find-cleerly-near-you. A physician order is required for both the scan and the Cleerly analysis.
Cleerly produces detailed reports. A patient receives precise quantification of plaque burden by type and location. The data is comprehensive. The question that follows is less straightforward: what should be done about these findings?
Most cardiologists have limited experience interpreting Cleerly reports. The platform is relatively new, and the detailed plaque characterization it provides exceeds what traditional training emphasized. A patient may receive a report showing significant soft plaque burden and find that their local cardiologist recommends the same interventions they would have recommended based on conventional risk factors alone: statins, blood pressure management, lifestyle modification.
The detailed data deserves an equally detailed response. Knowing that soft plaque exists is valuable. Knowing how to stabilize or reverse it requires expertise beyond standard cardiovascular care.
GRN Labs provides educational resources and data-driven audits that help individuals understand their Cleerly results in greater depth. Our review addresses questions that standard reports leave open: What factors may be contributing to plaque formation at the endothelial level? Is the glycocalyx intact? What biomarkers indicate whether nitric oxide production is compromised?
The GRN protocol tracks progress through biomarkers and, when appropriate, repeat imaging. The goal is measurable improvement over a defined timeframe, not indefinite management of static risk.
Have Cleerly results? Learn more about the GRN Vascular Review.
Watch the PresentationGRN Labs provides educational content and data-driven biomarker audits. We are not medical doctors, and nothing on this website constitutes medical advice, diagnosis, or treatment. This content is for informational purposes only and is not intended to replace the relationship between you and a qualified healthcare provider.
These statements have not been evaluated by the Food and Drug Administration (FDA). Any products or protocols discussed are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always consult your physician before beginning any new supplement, diet, or health regimen.